Summary
AMG Chart
Amgen Inc. (AMGN) Presents at Special Call (IR Call) Conference Transcript
Amgen Inc. (NASDAQ:AMGN ) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & Development Susan Sweeney - Executive Vice President of Obesity & Related Conditions Murdo Gordon - Executive Vice President of Global Commercial Operations Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Michael Yee - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Terence Flynn - Morgan Stanley, Research Division Trung Huynh - UBS Investment Bank, Research Division Evan Seigerman - BMO Capital Markets Equity Research David Amsellem - Piper Sandler & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Taylor Hanley - JPMorgan Chase & Co, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Courtney Breen - Sanford C.
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Amgen (AMGN) closed at $272.44, marking a -5.84% move from the previous day.
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Efficacy The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep Apnea Will be Initiated in 2025 THOUSAND OAKS, Calif. , June 23, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently.
Amgen Inc. Dividends
 AMG 10 months ago | Other | €2.25 Per Share |
| AMG 16 May 2024 | Other | €2.25 Per Share |
| AMG 15 Feb 2024 | Other | €2.25 Per Share |
| AMG 16 Nov 2023 | Other | €2.13 Per Share |
| AMG 17 Aug 2023 | Other | €2.13 Per Share |
Amgen Inc. Earnings
| 4 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| AMG 10 months ago | Other | €2.25 Per Share |
| AMG 16 May 2024 | Other | €2.25 Per Share |
| AMG 15 Feb 2024 | Other | €2.25 Per Share |
| AMG 16 Nov 2023 | Other | €2.13 Per Share |
| AMG 17 Aug 2023 | Other | €2.13 Per Share |
| 4 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
Amgen Inc. (AMG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Amgen Inc. ever had a stock split?
Amgen Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Bradway CEO | XDUS Exchange | US0311621009 ISIN |
| US Country | 28,000 Employees | 16 May 2025 Last Dividend | 22 Nov 1999 Last Split | 17 Jun 1983 IPO Date |
Overview
Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.
Products and Services
- Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
- Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
- Prolia - Addresses osteoporosis in postmenopausal women.
- XGEVA - Prevents skeletal-related events.
- Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
- Nplate - Treats immune thrombocytopenia.
- KYPROLIS - For relapsed or refractory multiple myeloma patients.
- Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
- EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
- Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
- BLINCYTO - For patients with acute lymphoblastic leukemia.
- TEPEZZA - Treats thyroid eye disease.
- KRYSTEXXA - Addresses chronic refractory gout.
- Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.
Contact Information
